



CRO LEADERSHIP AWARDS 2024

JUNE 2024

PRESENTED BY



**CLINICAL
LEADER**

SUPPORTED BY



**LIFE SCIENCE
CONNECT**

RESEARCH CONDUCTED BY:



Smarter questions • Smarter answers

Getting A Grasp
On CRO Selection

4

CRO
Awards

6

Category
Winners

7

Company
Profiles

16




CLINICAL LEADER

THEMED NEWSLETTERS

PERSONALIZE YOUR EXPERIENCE

Pick from topics you are interested in and receive **only** the newsletters you select.



SUBSCRIBE AND SELECT YOUR NEWSLETTER THEME PREFERENCES
clinicalleader.com/user/new






LIFE SCIENCE CONNECT



DATA-DRIVEN TOOLS FOR NAVIGATING THE CLINICAL RESEARCH SPACE

Impactful primary market research designed to offer insight into technology adoption, market dynamics, service provider selection, and service provider performance.

Recent reports include:



Getting A Grasp On CRO Selection

REBECCA MCAVOY Chief Research Officer, Industry Standard Research

The CRO selection process is a complicated one. Many factors come into play during this process, including individual trial needs, contractual arrangements, prior experience with providers, and personal preferences, just to name a few. One critical factor is undoubtedly the presence of preferred provider agreements (PPAs). Companies can spend a great deal of time negotiating these agreements, and their presence, or lack thereof, can make or break which CROs are shortlisted or awarded a Phase 2/3 study.

ISR delves into service provider selection and performance in our Phase 2/3 CRO Benchmarking Study, now in its 16th year. Because preferred provider agreements can play such pivotal roles in provider selection, we tailor our research questions to ensure that they reflect the relevant decision-making scenario(s) for each respondent. First, we must understand which respondents have preferred provider agreements for Phase 2/3 services.

Among the 232 Phase 2/3 outsourcers surveyed in ISR's most recent study, over half (57%) have preferred provider agreements in place. Company size has strong ties to the usage of preferred provider agreements, with a significantly higher proportion of respondents from large sponsors (88%) reporting that they use preferred provider agreements as compared to those from midsize sponsors (54%) and small sponsors (16%).

ISR then asks respondents to share their top CRO selection criteria in a manner that reflects the roles preferred provider agreements can play in the decision-making process. Respondents whose companies have preferred providers are asked about the importance of selection criteria in two different scenarios: first, choosing from among their preferred providers and, second, choosing a provider that is not on their preferred provider list. Respondents whose companies do not use PPAs are asked about their selection criteria in a general fashion. The Venn diagram in Figure 2 is used to portray the similarities and differences in the importance of selection criteria across these three scenarios. The top seven most important attributes in each scenario are shown.

The attributes in the center of the Venn diagram represent the selection criteria respondents deemed among the most important across all three scenarios: choosing from among preferred providers, choosing a provider not on a preferred list, or choosing with no preferred provider list. "Operational excellence" has been a critical and all-encompassing attribute for project delivery over the years. "Therapeutic expertise" is




Figure 1: "Does your company have formal preferred provider agreements for Phase 2/3 services?" (n=232)




Figure 2

valued regardless of the decision-making scenario, as a thorough understanding of the therapeutic area is key to effective trial execution. “Experience with similar study types” is also important across the board, suggesting that CROs should provide examples of success with similar trials. Finally, “Expectations for data quality” has become more important recently, landing in the center of the Venn for the past three years.

Some interesting findings emerge when examining the differences among the three scenarios. For example, respondents whose companies do not have preferred providers place more importance on “Local market/Regulatory knowledge” than do respondents whose companies have preferred providers. This may be tied to the fact that respondents without PPAs are more likely to work at small companies that may not have as much in-house expertise with regulatory requirements across multiple geographies.

Another noteworthy nuance is that “Offers innovative solutions” appears as a uniquely important factor for those who are deviating from their preferred provider list. Some trials may require specialized approaches or knowledge that necessitate searching beyond the capabilities of their preferred providers.

All of this analysis now begs the question of how to put it to use. Understanding CRO selection criteria is essential for both biopharma outsourcers and CROs. Decision makers at sponsor organizations can use the insights of


their peers to enhance their own approaches to Phase 2/3 outsourcing. Leadership and business development staff at CROs can use this information to better tailor their outreach and messages to target sponsors more effectively. To make these data even more powerful, coupling a grasp of sponsor selection priorities with provider performance metrics can lead to even more confident CRO selections for sponsors and marketing for CROs. ▶



➔ REBECCA MCAVOY is chief research officer, Industry Standard Research.

Survey Methodology: Industry Standard Research is a full-service market research provider to the pharma and pharma services industries. ISR’s CRO Quality Benchmarking research is conducted annually via an online survey. For the 2024 CRO Awards data, 42 service providers were evaluated on 20+ different performance metrics. Research participants were recruited from biopharmaceutical companies of all sizes and are screened for decision-making influence and authority when it comes to working with CROs. **Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months.** This level of qualification ensures that quality ratings come from actual involvement with a business and that companies identified as leaders are backed by experiential data.

For more information, please visit www.ISRreports.com.



CRO LEADERSHIP AWARDS 2024

The pharma and biopharma executives in *Clinical Leader's* and *Life Science Connect's* readership have told us about their struggles in efficiently vetting potential CRO partners. In response to this input, the CRO Leadership Awards were developed.

Based on research from Industry Standard Research's Contract Research Organization Quality Benchmarking annual online survey, 42 contract research organizations were evaluated on more than 20 different performance metrics. Research participants were recruited from biopharmaceutical companies of all sizes and were screened for decision-making influence and authority when it comes to working with contract research organizations. Respondents only evaluated companies with which they have worked on an outsourced project in the past 18 months. This level of qualification ensures that quality ratings come from actual involvement with a business and that companies identified as leaders are backed by experiential data. CROs have an opportunity to win these awards in up to three groups of outsourcing respondents – Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma).

We also recognize those companies that scored one standard deviation or more above the weighted average in each of the core categories. You will see these companies noted as the *Champions*.

WHAT ARE THE AWARDS?

ISR's survey participants were asked to provide an expectation rating for each CRO they have worked with in the past 18 months. Points were then totaled for a combined score for each attribute, and a composite score for each core category was determined. Winning CROs were identified when comparing their overall score vs. the competitive set.

To learn more about ISR's industry reports, and customized research, or to be included in future CRO Leadership Awards annual surveys, visit isrreports.com or contact ISR at (919) 301-0106.

PRESENTED BY:



**CLINICAL
LEADER**



**LIFE SCIENCE
CONNECT**

RESEARCH CONDUCTED BY:



Smarter questions .: Smarter answers

CRO LEADERSHIP AWARDS 2024 CAPABILITIES

- ▶ Access to patient populations
- ▶ Access to “unique” tests, machines, equipment
- ▶ Biostatistics
- ▶ Central lab
- ▶ Data management
- ▶ Investigator recruitment
- ▶ Monitoring
- ▶ Patient/volunteer recruitment (Phase 1)
- ▶ Patient recruitment (Phase 2/3)
- ▶ Speed of site start-up
- ▶ Technology for real-time access to data

CAPABILITIES



CHAMPIONS

OVERALL

ClinChoice
Caidya

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

CHDR
Lambda Therapeutic Research
ProPharma
Duke Clinical Research Institute
Precision for Medicine
Celerion
SGS Health Science
The PPD clinical research business of Thermo Fisher Scientific
ICON
Fortrea
IQVIA
Worldwide Clinical Trials
Parexel

BIG PHARMA

Precision for Medicine
Worldwide Clinical Trials
Medpace
Fortrea
ICON

SMALL PHARMA

Lambda Therapeutic Research
CHDR
Celerion
Innovaderm Research Inc.
The PPD clinical research business of Thermo Fisher Scientific
Caidya
IQVIA
Eurofins BioPharma Services
Novum
Altasciences
Precision for Medicine
Parexel
ICON

The terms “Small Pharma” and “Big Pharma” pertain to the outsourcing respondents, not the winners. “Overall” is a combination of Big and Small Pharma. To be recognized as a Champion, company must have scored one standard deviation or more above the weighted average in the particular category respondent group.

CRO LEADERSHIP AWARDS 2024 COMPATIBILITY

- ▶ Easy to work with
- ▶ Responsiveness
- ▶ Timely project communications

COMPATIBILITY



CHAMPIONS

OVERALL

CHDR
SGS Health Science
Caidya

BIG PHARMA

SGS Health Science
Worldwide Clinical Trials

SMALL PHARMA

CHDR

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

ClinChoice
ProPharma
Worldwide Clinical Trials
Allucent
The PPD clinical research business of Thermo Fisher Scientific
Lambda Therapeutic Research
ICON
Precision for Medicine
PSI CRO AG
IQVIA

BIG PHARMA

Medpace
Precision for Medicine
Syneos Health
ICON

SMALL PHARMA

Caidya
The PPD clinical research business of Thermo Fisher Scientific
Allucent
Worldwide Clinical Trials
Lambda Therapeutic Research
Precision for Medicine
IQVIA
ICON
ProPharma

The terms "Small Pharma" and "Big Pharma" pertain to the outsourcing respondents, not the winners. "Overall" is a combination of Big and Small Pharma. To be recognized as a Champion, company must have scored one standard deviation or more above the weighted average in the particular category respondent group.

CRO LEADERSHIP AWARDS 2024 EXPERTISE

- ▶ Local market/regulatory knowledge
- ▶ Operational excellence
- ▶ Scientific knowledge of the Phase 1 unit's lead investigator
- ▶ Study design expertise
- ▶ Therapeutic expertise

EXPERTISE



CHAMPIONS

OVERALL

Innovaderm Research Inc.
CHDR
ClinChoice

BIG PHARMA

Worldwide Clinical Trials

SMALL PHARMA

Innovaderm Research Inc.
CHDR

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

Duke Clinical Research Institute
Caidya
IQVIA
Worldwide Clinical Trials
Allucent
SGS Health Science
Novum
PSI CRO AG
ICON
ProPharma
The PPD clinical research business of Thermo Fisher Scientific
Parexel

BIG PHARMA

SGS Health Science
Precision for Medicine
Fortrea
Medpace
ICON
IQVIA

SMALL PHARMA

IQVIA
The PPD clinical research business of Thermo Fisher Scientific
Novum
Parexel
Allucent
ICON
Worldwide Clinical Trials

CRO LEADERSHIP AWARDS 2024 QUALITY

- ▶ Data quality
- ▶ Project manager quality

QUALITY



CHAMPIONS

OVERALL

CHDR
ClinChoice
Caidya

BIG PHARMA

Worldwide Clinical Trials

SMALL PHARMA

CHDR

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

Duke Clinical Research Institute
Worldwide Clinical Trials
SGS Health Science
ProPharma
Precision for Medicine
Celerion
ICON
The PPD clinical research business of Thermo Fisher Scientific
PSI CRO AG
Fortrea
Lambda Therapeutic Research
IQVIA

BIG PHARMA

SGS Health Science
Precision for Medicine
Medpace
Fortrea
ICON

SMALL PHARMA

Celerion
Caidya
The PPD clinical research business of Thermo Fisher Scientific
Worldwide Clinical Trials
ICON
Precision for Medicine
Lambda Therapeutic Research
IQVIA
Innovaderm Research Inc.
Quotient Sciences

The terms "Small Pharma" and "Big Pharma" pertain to the outsourcing respondents, not the winners. "Overall" is a combination of Big and Small Pharma. To be recognized as a Champion, company must have scored one standard deviation or more above the weighted average in the particular category respondent group.

CRO LEADERSHIP AWARDS 2024 RELIABILITY

- ▶ Meeting overall project timelines
- ▶ Operational excellence
- ▶ Staff turnover

RELIABILITY



CHAMPIONS

OVERALL

Duke Clinical Research Institute
ClinChoice
CHDR

BIG PHARMA

Worldwide Clinical Trials

SMALL PHARMA

CHDR

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

ProPharma
Caidya
Novum
SGS Health Science
Precision for Medicine
Celerion
The PPD clinical research business of Thermo Fisher Scientific
Worldwide Clinical Trials
ICON
PSI CRO AG
Medpace
IQVIA
Parexel

BIG PHARMA

Precision for Medicine
Medpace
SGS Health Science
Fortrea
ICON

SMALL PHARMA

The PPD clinical research business of Thermo Fisher Scientific
Novum
IQVIA
Innovaderm Research Inc.
ProPharma
Precision for Medicine
Caidya
Celerion
Quotient Sciences

Clinical research is a delicate ecosystem

**The right outsourcing decision will help
your program thrive**



The inSeption Difference

The Right Culture

Attracts a subset of high-performing people who are driven by personal accountability and excellence.

Continuity of Resources

Teams value your assets as you do and are committed to seeing your program through to completion.

Predictable Costs

Our high-quality of work and unique pricing model eliminates change orders and unexpected costs.

<6%

Employee
attrition vs
25-30% industry
average

97%

Customer
satisfaction vs
55% reported by
competitors

94%

Referral-based
business from
existing
relationships

Put your program in trusted hands.



info@inseptiongroup.com
inSeptionGroup.com

©2024 inSeption Group. All rights reserved. 04/24



CRO LEADERSHIP AWARDS

INDIVIDUAL ATTRIBUTE AWARDS

The Individual Attribute Awards were developed because of many conversations we have had with the readers of *Clinical Leader*. These conversations uncovered common attributes that sponsor companies identified as being imperative when choosing a supplier and deciding to continue doing business with a supplier.

They were often referred to as the ever-important “intangibles” a supplier brings to the table. Outside of the cover metrics of capabilities, compatibility, expertise, quality, and reliability, these attributes were what our readers identified as being most important, and as such, we felt it was important to share the data with other sponsor companies.

DATA QUALITY

TOP PERFORMERS

CHDR
Duke Clinical Research Institute
Caidya
ClinChoice

EXCEEDED CUSTOMER EXPECTATIONS

SGS Health Science
ProPharma
Lambda Therapeutic Research
Precision for Medicine
ICON
Fortrea
The PPD clinical research business of Thermo Fisher Scientific
IQVIA

MEETING PROJECT TIMELINES

TOP PERFORMERS

ClinChoice
Duke Clinical Research Institute

EXCEEDED CUSTOMER EXPECTATIONS

SGS Health Science
Innovaderm Research Inc.
ProPharma
Caidya
CHDR
Lambda Therapeutic Research
Quotient Sciences
Celerion
Worldwide Clinical Trials
ICON
The PPD clinical research business of Thermo Fisher Scientific
Precision for Medicine
Fortrea

OPERATIONAL EXCELLENCE

TOP PERFORMERS

CHDR
ClinChoice
Novum

EXCEEDED CUSTOMER EXPECTATIONS

PSI CRO AG
Worldwide Clinical Trials
Quotient Sciences
ICON
The PPD clinical research business of Thermo Fisher Scientific
IQVIA
Precision for Medicine
Caidya
Duke Clinical Research Institute
Medpace
ProPharma
Celerion



CRO LEADERSHIP AWARDS

INDIVIDUAL ATTRIBUTE AWARDS

TECHNOLOGY FOR ACCESS TO DATA

TOP PERFORMERS

ClinChoice

CHDR

EXCEEDED CUSTOMER EXPECTATIONS

Duke Clinical Research Institute

Precision for Medicine

Caidya

IQVIA

SGS Health Science

Worldwide Clinical Trials

ProPharma

Parexel

The PPD clinical research business
of Thermo Fisher Scientific

ICON

UBC

Novum

THERAPEUTIC EXPERTISE

TOP PERFORMERS

Duke Clinical Research Institute

ClinChoice

Innovaderm Research Inc.

EXCEEDED CUSTOMER EXPECTATIONS

PSI CRO AG

CHDR

Caidya

Novum

Allucent

Worldwide Clinical Trials

IQVIA

Parexel

Precision for Medicine

ICON

Celerion

Medpace

Eurofins BioPharma Services

KEY

- CAPABILITIES
- COMPATIBILITY
- EXPERTISE
- QUALITY
- RELIABILITY

WWW.CROLEADERSHIPAWARDS.COM



CATEGORIES WON: ● ●

Allucent

Cary, NC, USA
allucent.com

Phone: (919) 361-2286
Contact: Steffany Cox
Email: Steffany.Cox@allucent.com

KEY LOCATIONS: Cary, NC, USA; Bracknell, Berkshire, UK; Schiphol, Amsterdam, The Netherlands

DRUG LIFE CYCLE STAGES:

Research & Development: Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

MAIN SERVICE AREAS:

Pre-Clinical, Full-Service Clinical

SERVICES & CAPABILITIES: Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology in a wide range of therapeutic areas.

THERAPEUTIC AREAS: Allucent's therapeutic areas include: Oncology & Hematology, Neuroscience, Infectious Disease & Vaccine, Immunology & Inflammation, Allergy & Asthma, Cell & Gene Therapy, Pediatrics, Rare Diseases

INDIVIDUAL ATTRIBUTE AWARDS:

Therapeutic Expertise

CATEGORIES WON: ● ● ● ● ●

Caidya

Raleigh, NC, USA
caidya.com

Contact: Andrew Copestake
Email: andrew.copestake@caidya.com

KEY LOCATIONS: Sydney, Australia; São Paulo, Brazil; Shanghai, China; Eschborn, Germany; Krakow, Poland; Seoul, South Korea; Madrid, Spain; Buckinghamshire, United Kingdom

DRUG LIFE CYCLE STAGES:

Research & Development: Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

MAIN SERVICE AREAS:

Full-Service Clinical

SERVICES & CAPABILITIES: Caidya offers fit-for-purpose solutions across early-phase development & clinical pharmacology, clinical operations, clinical science, medical affairs, medical writing, regulatory affairs & strategy, data management, biostats & programming, drug safety & pharmacovigilance.

THERAPEUTIC AREAS: Oncology, Hematology, Immuno-oncology, Cell & Gene Therapy, Rare Disease, Neurology, Nephrology, Cardiology, Ophthalmology, Dermatology, Infectious Disease, Gastroenterology, Respiratory, Women's Health

INDIVIDUAL ATTRIBUTE AWARDS: Data Quality, Meeting Overall Project Timelines, Operational Excellence, Technology for Real-Time Access to Data, Therapeutic Expertise

CATEGORIES WON: ● ● ●

Celerion

Lincoln, NE, USA
celerion.com

Phone: (402) 476-2811
Contact: David Maya
Email: david.maya@celerion.com

KEY LOCATIONS: Lincoln, NE, USA; Tempe, AZ, USA; West Conshohocken, PA, USA; Montreal, QC, Canada; Belfast, Northern Ireland, UK; Zürich, Switzerland; Vienna, Austria

DRUG LIFE CYCLE STAGES:

Research & Development: Clinical (Phase 1, Phase 2)

MAIN SERVICE AREAS:

Lab, Full-Service Clinical

SERVICES & CAPABILITIES: Celerion excels at Phase 1-2 clinical pharmacology ranging from PK/PD, FIH, SAD/MAD, DDI, QTc, Bioequivalence, and ADME studies to multisite patient studies with full services (project management, data management, statistics, regulatory support & bioanalytical services).

THERAPEUTIC AREAS: Cardiovascular Disease, Renal Insufficiency, Hepatic Insufficiency, Immunotherapy, Infectious Disease, Metabolic Disease, Oncology, Respiratory Disease, Vaccines, and others

INDIVIDUAL ATTRIBUTE AWARDS: Meeting Overall Project Timelines, Operational Excellence, Therapeutic Expertise



CATEGORIES WON: ● ● ● ● ●

Duke Clinical Research Institute

Durham, NC, USA
dcri.org

Phone: (919) 668-8700
Contact: Carolyn Arias
Email: carolyn.arias@duke.edu

KEY LOCATIONS: Durham, NC

DRUG LIFE CYCLE STAGES:

Research & Development: Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

MAIN SERVICE AREAS:

Full-Service Clinical

SERVICES & CAPABILITIES: Our services include tailored trial design, collaborative academic leadership, established NA investigator networks, efficient data collection, risk-based monitoring, and shared endpoint adjudication.

THERAPEUTIC AREAS: Renowned for cardiology, we pioneer trials in GI health, infectious disease, neuroscience, oncology, pediatrics, and respiratory medicine. Our depth of knowledge is shared via impactful publications and global meetings.

INDIVIDUAL ATTRIBUTE AWARDS: Data Quality, Meeting Overall Project Timelines, Operational Excellence, Technology for Real-Time Access to Data, Therapeutic Expertise

CATEGORIES WON: ●

Eurofins BioPharma Services

Lancaster, PA, USA
eurofins.com/biopharma-services/

Email: clinicaltrials@bcl.eurofins.com

KEY LOCATIONS: The Eurofins BioPharma Services Network of Companies has a global footprint in the USA, Europe, and APAC regions.

DRUG LIFE CYCLE STAGES:

Research & Development: Discovery, Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

MAIN SERVICE AREAS:

Lab

SERVICES & CAPABILITIES: The Eurofins BioPharma Services Network of Companies is a first-class biopharmaceutical outsourcing services partner. The network covers the whole chain of drug development with a global footprint, uniform QA systems, and high-quality services.

THERAPEUTIC AREAS: Oncology, Cell & Gene Therapy, Vaccine Development, Cardiovascular Disease, Immunology, CNS, Gastroenterology, Pulmonary/Respiratory Diseases

INDIVIDUAL ATTRIBUTE AWARDS: Therapeutic Expertise

CATEGORIES WON: ● ● ● ● ●

Fortrea

Durham, NC, USA
fortrea.com

Email: GCOInsideSalesLeadership@fortrea.com

KEY LOCATIONS: Durham, NC, USA; Dallas, TX, USA; São Paulo, Brazil; Leeds, UK; Munich, Germany; Shanghai, China; Bangalore, India; Tokyo, Japan

DRUG LIFE CYCLE STAGES:

Research & Development: Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

MAIN SERVICE AREAS:

Full-Service Clinical

SERVICES & CAPABILITIES: Integrated clinical pharmacology solutions, Phase 1 through Phase 4 full-service clinical development, FSP and hybrid models, diagnostic and device development, regulatory strategy, development, market access, and HEOR consulting

THERAPEUTIC AREAS: Cardiovascular and metabolism; cell, gene, and advanced therapies; hepatology; immunology and inflammation; infectious diseases and vaccines; nephrology; neurology and ophthalmology; oncology; rare disease and pediatrics; respiratory; metabolic diseases; rare disease; and immunology

INDIVIDUAL ATTRIBUTE AWARDS: Data Quality, Meeting Overall Project Timelines

KEY

- CAPABILITIES
- COMPATIBILITY
- EXPERTISE
- QUALITY
- RELIABILITY

WWW.CROLEADERSHIPAWARDS.COM



CATEGORIES WON: ● ● ● ● ●

ICON

Dublin, Ireland
iconplc.com

Phone: +353 (1) 291 2000
Contact: Lisa King
Email: Lisa.King@iconplc.com

KEY LOCATIONS: Dublin, Ireland; Paris, France; Reading, United Kingdom; Blue Bell, PA, USA; Raleigh, NC, USA; Tokyo, Japan; Sydney, Australia; São Paulo, Brazil

DRUG LIFE CYCLE STAGES:

Research & Development: Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

MAIN SERVICE AREAS: Lab, Full-Service Clinical

SERVICES & CAPABILITIES: ICON offers a full range of clinical, consulting, and commercial services from clinical development strategy, planning, and trial design to full study execution and post-market commercialization.

THERAPEUTIC AREAS: Oncology, Central Nervous Systems, Infectious Diseases and Vaccines, Cell and Gene Therapies, Cardiovascular, Endocrine and Metabolic, Ophthalmology, Paediatrics, Women's Health, Internal Medicine, and Immunology

INDIVIDUAL ATTRIBUTE AWARDS: Data Quality, Meeting Overall Project Timelines, Operational Excellence, Technology for Real-Time Access to Data, Therapeutic Expertise

CATEGORIES WON: ● ● ● ●

Innovaderm Research Inc.

Montreal, QC, Canada
innovaderm.com/full-service-dermatology-cro

Phone: 1-866-575-3111
Contact: Audrey Miron
Email: busdev@innovaderm.com

KEY LOCATIONS: Barcelona, Spain; Warsaw, Poland; California, USA; Florida, USA; Boston, MA, USA; New York, USA; Edmonton, AB, Canada; Toronto, ON, Canada; Montreal, QC, Canada

DRUG LIFE CYCLE STAGES:

Research & Development: Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

MAIN SERVICE AREAS: Full-Service Clinical

SERVICES & CAPABILITIES: Innovaderm is THE leading full-service dermatology CRO built upon deep dermatology expertise and proven success, offering full operational capabilities for all phases of clinical development toward the benefit of improving patients' lives.

THERAPEUTIC AREAS: 30+ dermatology indications including: Acne, Alopecia Areata, Atopic Dermatitis, Hidradenitis Suppurativa, Notalgia Paresthetica, Psoriasis, PPP, GPP, Rosacea, and more. Dermal Fillers & other Medical Aesthetics trials. Systemic Sclerosis & other Rheumatology indications.

INDIVIDUAL ATTRIBUTE AWARDS: Meeting Overall Project Timelines, Therapeutic Expertise

CATEGORIES WON: ● ● ● ● ●

IQVIA

Durham, NC, USA
iqvia.com

Contact: Jonathan Limbouris
Email: jonathan.limbouris@iqvia.com

KEY LOCATIONS: Global

DRUG LIFE CYCLE STAGES:

Research & Development: Discovery, Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Drug Substance Production

MAIN SERVICE AREAS: Lab, Full-Service Clinical

SERVICES & CAPABILITIES: IQVIA offers full service and functional service models to support pharma companies in Phase I-3 research, including patient recruitment and retention, clinical monitoring, life cycle safety, laboratory services, data management, biostatistics, and medical writing.

THERAPEUTIC AREAS: Oncology, CNS, Infectious Disease & Vaccines, Cardiovascular, Dermatology, GI & Hepatology, Endocrinology, Allergy & Respiratory, Rheumatology, Ophthalmology, Nephrology, & Reproductive Health

INDIVIDUAL ATTRIBUTE AWARDS: Data Quality, Operational Excellence, Technology for Real-Time Access to Data, Therapeutic Expertise

M E D P A C E **parexel** **propharma**

CATEGORIES WON: ● ● ● ● ●

Medpace

Cincinnati, OH, USA
medpace.com

Phone: (513) 579-9911
Contact: Business Development
Email: info@medpace.com

KEY LOCATIONS: Cincinnati, OH, USA; Shanghai, China; Singapore; Tokyo, Japan; Leuven, Belgium; London, UK; München, Germany; Warsaw, Poland

DRUG LIFE CYCLE STAGES:

Research & Development: Clinical (Phase 1, Phase 2, Phase 3)

MAIN SERVICE AREAS: Full-Service Clinical

SERVICES & CAPABILITIES: A full range of integrated services: Medical Affairs, Regulatory, Clinical Monitoring, Clinical Trial Management, Biometrics, Safety & Pharmacovigilance, Quality Assurance, Technology

THERAPEUTIC AREAS: Autoimmune Diseases, Cardiovascular, Cellular & Gene Therapies, Dermatology, Endocrine & Metabolic, Gastroenterology, Hematology & Oncology, Infectious Diseases & Vaccines, Hepatology, Nephrology, Neuroscience, Ophthalmology, Pediatrics, Radiation Therapy, Rare Disease & Orphan Indications, Women's Health

INDIVIDUAL ATTRIBUTE AWARDS:

Operational Excellence, Therapeutic Expertise

CATEGORIES WON: ● ● ● ●

Parexel

Durham, NC, USA
parexel.com

Phone: (919) 544-3170
Contact: Benjamin Doff
Email: Benjamin.Doff@parexel.com

KEY LOCATIONS: Durham, NC, USA; Newton, MA, USA; Hyderabad, India; Tokyo, Japan; Uxbridge, UK; Buenos Aires, Argentina; Berlin, Germany; Shenyang, China

DRUG LIFE CYCLE STAGES:

Research & Development: Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

Formulated Drug Production: Packaging, Logistics

MAIN SERVICE AREAS: Lab, Full-Service Clinical

SERVICES & CAPABILITIES: From clinical trials to regulatory and consulting to commercial and market access, our therapeutic, technical, and functional ability and services help life sciences and biopharmaceutical clients transform their scientific discoveries into treatments.

THERAPEUTIC AREAS: Oncology, hematology, infectious disease & vaccines, neurology, respiratory, dermatology, endocrine & metabolism, rheumatology, cardiovascular, gastroenterology, genitourinary & nephrology, psychiatry, ophthalmology, allergy & immunology, women's health, and orthopedics

INDIVIDUAL ATTRIBUTE AWARDS: Technology for Real-Time Access to Data, Therapeutic Expertise

CATEGORIES WON: ● ● ● ● ●

ProPharma

Raleigh, NC, USA
propharmagroup.com

Contact: Sara Sorrentino
Email: sara.sorrentino@propharmagroup.com

KEY LOCATIONS: Raleigh, NC, USA; Chicago, IL, USA; London, UK; Leiden, Netherlands; Lund, Sweden; Berlin, Germany. Regions: Central Eastern Europe; Australia; Japan; China; India

DRUG LIFE CYCLE STAGES:

Research & Development: Discovery, Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

Drug Substance Production: Primary Process Development

MAIN SERVICE AREAS: Pre-Clinical, Full-Service Clinical

SERVICES & CAPABILITIES: ProPharma's deep domain expertise in regulatory affairs, clinical research, quality & compliance, pharmacovigilance, medical information, & R&D tech offers an end-to-end suite of fully customizable solutions that de-risk & accelerate drug & device programs for sponsors.

THERAPEUTIC AREAS: ProPharma offers custom & proven solutions across the following therapeutic areas: Oncology, Rare Disease, Cell & Gene Therapy, Cardiovascular, Cell & Gene Therapy, Central Nervous System (CNS), Infectious Disease/Vaccines, Ophthalmology, Pediatrics, Respiratory System, Blood Diseases, and Immune System.

INDIVIDUAL ATTRIBUTE AWARDS: Data Quality, Meeting Overall Project Timelines, Operational Excellence, Technology for Real-Time Access to Data

KEY

● CAPABILITIES

● COMPATIBILITY

● EXPERTISE

● QUALITY

● RELIABILITY

WWW.CROLEADERSHIPAWARDS.COM



CATEGORIES WON: ● ● ● ●

PSI CRO AG

Zug, Switzerland
psi-cro.com/

Phone: +41 41 228 10 00
Contact: Olga Alfonsova
Email: olga.alfonsova@psi-cro.com

KEY LOCATIONS: Zug, Switzerland; Philadelphia, PA, USA; San Francisco, CA, USA; Warsaw, Poland; Munich, Germany; Buenos Aires, Argentina; Sydney, Australia; Seoul, South Korea

DRUG LIFE CYCLE STAGES:

Research & Development: Clinical (Phase 2, Phase 3)

MAIN SERVICE AREAS: Full-Service Clinical

SERVICES & CAPABILITIES: PSI CRO is a privately owned, full-service CRO operating globally. PSI's global reach supports clinical trials across multiple countries and continents and specializes in the planning and execution of global pivotal registration clinical trials.

THERAPEUTIC AREAS: Oncology, including breast cancer, lung cancer, prostate cancer, colorectal cancer, ovarian cancer, and radiopharmaceuticals; hematology-oncology and hemophilia; gastrointestinal diseases, including Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases

INDIVIDUAL ATTRIBUTE AWARDS:

Operational Excellence, Therapeutic Expertise

CATEGORIES WON: ● ●

Quotient Sciences

Nottingham, UK
quotientsciences.com

Email: info@quotientsciences.com

KEY LOCATIONS: Garnet Valley (Philadelphia area), PA, USA; Boothwyn (Philadelphia area), PA, USA; Miami, FL, USA; Nottingham, UK; Edinburgh, UK; Reading, UK; Alnwick, UK

DRUG LIFE CYCLE STAGES:

Research & Development: Pre-Clinical, Clinical (Phase 1, Phase 2)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

MAIN SERVICE AREAS: Lab, Pre-Clinical, Full-Service Clinical

SERVICES & CAPABILITIES: Drug substance (API) synthesis & development, API manufacturing, drug product formulation development, drug product manufacturing, Phase 1 clinical trials with healthy volunteers, bioanalysis, human ADME, 14C radiolabeled drug substance, data sciences, and clinical pharmacology

THERAPEUTIC AREAS: Orphan Drugs for Rare Diseases, Oncology, Pediatrics, Cardiology, Gastroenterology/GI, Pain Management, CNS & Neurology, Psychedelic Therapeutics

INDIVIDUAL ATTRIBUTE AWARDS: Meeting Overall Project Timelines, Operational Excellence

CATEGORIES WON: ● ● ● ● ●

SGS Health Science

Geneva, Switzerland
sgs.com/healthscience

Phone: +41 22 739 91 11
Contact: SGS Health Science
Email: healthscience@sgs.com

KEY LOCATIONS: Geneva, Switzerland; Antwerp, Belgium; Mississauga, ON, Canada; Lincolnshire, IL, USA; Berlin, Germany; Glasgow, Dumbartonshire, UK; Shanghai, China; Paris, France

DRUG LIFE CYCLE STAGES:

Research & Development: Discovery, Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

MAIN SERVICE AREAS: Lab, Pre-Clinical, Full-Service Clinical

SERVICES & CAPABILITIES: Formulation development, quality control testing for raw materials, APIs, and finished products; manufacturing for Phase 1-3 clinical trials; full clinical research services with an SGS clinical pharmacology unit, central lab services, and bioanalysis

THERAPEUTIC AREAS: SGS supports all therapeutics areas with formulation, QC testing, clinical manufacturing and clinical research. SGS clinical research services specialize in infectious disease, respiratory, and CNS.

INDIVIDUAL ATTRIBUTE AWARDS: Data Quality, Meeting Overall Project Timelines, Technology for Real-Time Access to Data



CATEGORIES WON: ●

Syneos Health

Morrisville, NC, USA
syneoshealth.com

Email: meg.byers@syneoshealth.com

KEY LOCATIONS: Syneos Health has offices in North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

DRUG LIFE CYCLE STAGES:

Research & Development: Discovery, Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

MAIN SERVICE AREAS: Full-Service Clinical

SERVICES & CAPABILITIES: Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs, and commercial insights into outcomes to address modern market realities.

THERAPEUTIC AREAS: Biosimilars, Cardiovascular, Cell & Gene Therapy, Neuroscience, Dermatology, Endocrine & Metabolic, Gastroenterology, Immunology & Inflammation, Infectious Diseases, Oncology & Hematology, Pediatrics, Rare Disease, Respiratory, Women's Health, and more



CATEGORIES WON: ●●●●●

The PPD clinical research business of Thermo Fisher Scientific

Wilmington, NC, USA
thermofisher.com/ppd

Email: salesops@ppd.com

KEY LOCATIONS: Wilmington, NC, USA; Research Triangle Park, NC, USA; Middleton, WI, USA; Richmond, VA, USA; Austin, TX, USA; China; Japan; Asia-Pacific; UK; Europe; Middle East; Africa; Latin America

DRUG LIFE CYCLE STAGES:

Research & Development: Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

MAIN SERVICE AREAS: Lab, Full-Service Clinical

SERVICES & CAPABILITIES: Phase 1-3b clinical development & laboratory services: bioanalytical, biomarkers, central, GMP, vaccine sciences; AI/ML; biotech; digital/decentralized trials; FSP; peri- and post-approval; RWE/RWD; site/patient services; vaccine development

THERAPEUTIC AREAS: Cardiovascular, Cell/ Gene Therapy, Critical Care, Dermatology, Gastrointestinal, Immunology, Infectious Diseases, Metabolic/Endocrine, Neuroscience, Oncology/ Hematology, Pediatrics, Rare Diseases, Respiratory, Urology, Vaccines, Women's Health, and more

INDIVIDUAL ATTRIBUTE AWARDS: Data Quality, Meeting Overall Project Timelines, Operational Excellence, Technology for Real-Time Access to Data



CATEGORIES WON: ●●●●●

Worldwide Clinical Trials

Research Triangle Park, NC, USA
worldwide.com

Email: OfficeofCEO@worldwide.com

KEY LOCATIONS: Research Triangle Park, NC, USA; Austin, TX, USA; Boston, MA, USA; Warsaw, Poland; Belgrade, Serbia; Nottingham, UK; São Paulo, Brazil; Tokyo, Japan

DRUG LIFE CYCLE STAGES:

Research & Development: Discovery, Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3, Phase 4)

Formulated Drug Production: Logistics

MAIN SERVICE AREAS: Lab, Pre-Clinical, Full-Service Clinical

SERVICES & CAPABILITIES: Bioanalytical laboratory services, Phase 1-4 clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring a collaborative, personalized approach to each clinical program.

THERAPEUTIC AREAS: Neuroscience, Oncology, Rare Disease, and Cardiometabolic and Inflammatory Disease

INDIVIDUAL ATTRIBUTE AWARDS: Meeting Overall Project Timelines, Operational Excellence, Technology for Real-Time Access to Data, Therapeutic Expertise

KEY

● CAPABILITIES

● COMPATIBILITY

● EXPERTISE

● QUALITY

● RELIABILITY

WWW.CROLEADERSHIPAWARDS.COM



CATEGORIES WON: ●

Altasciences

Laval, QC, Canada
altasciences.com

Email: contact@altasciences.com

KEY LOCATIONS: Laval, QC, Canada;
Montréal, QC, Canada; Kansas City, KS, USA;
Seattle, WA, USA; Philadelphia, PA, USA;
Los Angeles, CA, USA; Scranton, PA, USA;
Columbia, MO, USA; Sacramento, CA, USA

DRUG LIFE CYCLE STAGES:

Research & Development: Pre-Clinical, Clinical (Phase 1, Phase 2)

Formulated Drug Production: Dosage Form Development, Dosage Form Production

MAIN SERVICE AREAS:

Lab, Pre-Clinical, Full-Service Clinical

SERVICES & CAPABILITIES: Altasciences is an integrated CRO/CDMO offering a flexible approach to pre-clinical and clinical pharmacology studies, including bioanalysis, formulation, manufacturing, and analytical services. Other services include program management, medical writing, and biostatistics.

THERAPEUTIC AREAS: Therapeutic areas include (but are not limited to) the following: cardiology, dermatology, gastroenterology, immunology, CNS/neurology, oncology, ophthalmology, substance abuse, psychiatry, rheumatology, urology, infectious diseases, and metabolism and endocrinology.

cell & gene
THE PODCAST

Join us as **Cell & Gene** Chief Editor Erin Harris interviews industry and academic leaders on what they're working on and how it's moving the sector forward. Each episode of **Cell & Gene: The Podcast** will explore approved and pipeline therapies; new trends in manufacturing; the long, regulated road to commercialization; and everything in between.

Listen on **Apple Podcasts**

Listen on **Spotify Podcasts**

Listen on **Google Podcasts**

BROUGHT TO YOU BY



CLINICAL
LEADER

RESEARCH BY



SUPPORTED BY



LIFE SCIENCE
CONNECT



CRO LEADERSHIP AWARDS 2024

WHAT FACET OF YOUR
TRIALS
DO YOU WANT TO
IMPROVE ?

The CRO Leadership Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource clinical trials. Learn more about the survey methodology behind the awards and see the 2024 winners at croleadershipawards.com.

Clinical Research. Evolved.

With a singular focus on clinical research and commercialisation, ICON offers highly focused, integrated services and solutions that strategically and proactively solve today's challenges.

[ICONplc.com](https://www.iconplc.com)

